Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;148(1):1-14.
doi: 10.1007/s00432-021-03815-z. Epub 2021 Oct 5.

Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective

Yu-Chi Chen #  1 , Wei Shi #  1 , Jia-Jie Shi  2 , Jin-Jian Lu  3   4   5
Affiliations
Review

Progress of CD47 immune checkpoint blockade agents in anticancer therapy: a hematotoxic perspective

Yu-Chi Chen et al. J Cancer Res Clin Oncol. 2022 Jan.

Abstract

CD47, a transmembrane protein, acts as a "do not eat me" signal that is overexpressed in many tumor cell types, thereby forming a signaling axis with its ligand signal regulatory protein alpha (SIRPα) and enabling the tumor cells to escape from macrophage-mediated phagocytosis. Several clinical trials with CD47 targeting agents are underway and have achieved impressive results preliminarily. However, hematotoxicity (particularly anemia) has emerged as the most common side effect that cannot be neglected. In the development of CD47 targeting agents, various methods have been used to mitigate this toxicity. In this review, we summarized five strategies used to alleviate CD47 blockade-induced hematotoxicity, as follows: change in the mode of administration; dual targeting bispecific antibodies of CD47; CD47 antibodies/SIRPα fusion proteins with negligible red blood cell binding; anti-SIRPα antibodies; and glutaminyl-peptide cyclotransferase like inhibitors. With these strategies, the development of CD47 targeting agents can be improved.

Keywords: Anemia; CD47/SIRPα; Immunotherapy; Macrophages; Phagocytosis checkpoint.

PubMed Disclaimer

Conflict of interest statement

The authors declared that there is no conflict of interest.

Figures

Fig. 1
Fig. 1
Anti-CD47 antibodies induce hematotoxicity. A Anti-CD47 antibodies activate phagocytosis of RBCs by macrophages. B Anti-CD47 antibodies bind to different RBCs to cause RBC agglutination. Ab antibody, MΦ macrophage
Fig. 2
Fig. 2
Strategies to diminish CD47 blockade induced hematotoxicity. A The priming low dose of CD47 antibody is administered to eliminate aged RBCs and lead to compensatory of reticulocytes. A higher maintenance dose is administered for better treatment. B Dual-targeting bispecific antibodies that target both tumor-associated antigen and CD47 can reduce RBCs binding while ensuring the binding to tumor cells. C CD47 antibodies/SIRPα fusion proteins with negligible RBC binding can reduce hematotoxicity. D Anti-SIRPα antibody does not eliminate RBCs while blocking the CD47/SIRPα pathway. E QPCTL inhibitors block the CD47/SIRPα pathway by altering the post-translational modification of CD47 and do not cause hematotoxicity. Ab antibody, MΦ macrophage, TAA tumor-associated antigen, Fp fusion protein, w/o pGlu without pyroglutamate modification
See this image and copyright information in PMC

References

    1. Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N et al (2018) CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N Engl J Med 379(18):1711–1721 - DOI - PMC - PubMed
    1. Agoram B, Wang B, Sikic BI, Lakhani NJ, Patnaik A, Liu J et al (2018) Pharmacokinetics of Hu5F9-G4, a first-in-class anti-CD47 antibody, in patients with solid tumors and lymphomas. J Clin Oncol 36(15_suppl):2525 - DOI
    1. Ansell S, Chen RW, Flinn IW, Maris MB, O’Connor OA, Johnson LD et al (2016) A phase 1 study of TTI-621, a novel immune checkpoint inhibitor targeting CD47, in patients with relapsed or refractory hematologic malignancies. Blood 128(22):1812 - DOI
    1. Ansell SM, Flinn IW, Maris MB, O’Connor OA, Lesokhin A, Advani AS et al (2017) TTI-621 (SIRPαFc), an immune checkpoint inhibitor blocking the CD47 “do not eat” signal, induces objective responses in patients with advanced, relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Blood 130(Supplement 1):4116
    1. Ansell SM, Maris MB, Lesokhin AM, Chen RW, Flinn IW, Sawas A et al (2021) Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 27(8):2190–2199 - DOI - PubMed

MeSH terms